Research and Development

Tony Green discusses the difficulty in pinning down his diagnosis of the irregular heart rhythm condition, until his use of …

Novartis has announced that it will expand its current partnership with Pear Therapeutics, signed in March, as it reveals that …

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

Norton Rose Fulbright’s Dominic Stuttaford, James Baillieu and Susie Brain discuss the implications regarding the recent reforms to cross-border royalties.The …

Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, …

Frequency Therapeutics is a biotech with big ideas and it has made a big appointment to back up those ideas, …

The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …

Manufacturing issues at the single Pfizer plant that produces the EpiPen epinephrine injector has caused serious shortages in the UK …

Amgen has lifted the curtain on complete Phase 3 data for its calcitonin gene-related peptide receptor (CGRP) inhibitor Aimovig (erenumab) in …

After a busy start to the year, with a number of acquisitions and a few divestments, Sanofi’s Chief Financial Officer, …

GW Pharma are inching step by step towards a likely approval with the FDA, after it received a strong recommendation …

Novartis has revealed it is to invest $100 million into the research and development of new treatments for malaria over …

Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …

When it comes to the pharmaceutical supply chain, patient safety has and will always be a primary concern for all …

Novartis has lifted the curtain on new data from a Phase 3 trial investigating the efficacy of Entresto (sacubitril/valsartan) in …